-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
-
Summary
-
Endonovo Therapeutics, Inc. quarterly/annual Nonoperating Income (Expense) history and growth rate from 2019 to 2022.
- Endonovo Therapeutics, Inc. Nonoperating Income (Expense) for the quarter ending September 30, 2023 was -$293K, a 175% decline year-over-year.
- Endonovo Therapeutics, Inc. Nonoperating Income (Expense) for the twelve months ending September 30, 2023 was -$1.79M, a 20618% decline year-over-year.
- Endonovo Therapeutics, Inc. annual Nonoperating Income (Expense) for 2022 was -$15.2M, a 1632% decline from 2021.
- Endonovo Therapeutics, Inc. annual Nonoperating Income (Expense) for 2021 was -$878K, a 135% decline from 2020.
- Endonovo Therapeutics, Inc. annual Nonoperating Income (Expense) for 2020 was $2.52M.
Nonoperating Income (Expense), Trailing 12 Months (USD)
Nonoperating Income (Expense), Annual (USD)
Nonoperating Income (Expense), YoY Annual Growth (%)